Overview

A Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Ethionamide Alone and in Combination With BVL-GSK098

Status:
Not yet recruiting

Trial end date:
2023-10-01

Target enrollment:

Participant gender:

Summary

To evaluate the 7-day early bactericidal activity (EBA), pharmacokinetics (PK), safety and tolerability of ethionamide (Eto) with or without BVL-GSK098 in participants with rifampicin- and isoniazid-susceptible pulmonary TB.

Phase:

Phase 2

Details

Lead Sponsor:

TASK Applied Science

Treatments:

Ethionamide
Isoniazid